Cargando…
Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center
BACKGROUND: Although mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines report >90% efficacy, breakthrough infections occur. Little is known about their effectiveness against SARS-CoV-2 variants, including the highly prevalent B.1.427/B.1.429 variant. METHODS: In thi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344553/ https://www.ncbi.nlm.nih.gov/pubmed/34137815 http://dx.doi.org/10.1093/cid/ciab554 |
_version_ | 1783734482775310336 |
---|---|
author | Jacobson, Karen B Pinsky, Benjamin A Montez Rath, Maria E Wang, Hannah Miller, Jacob A Skhiri, Mehdi Shepard, John Mathew, Roshni Lee, Grace Bohman, Bryan Parsonnet, Julie Holubar, Marisa |
author_facet | Jacobson, Karen B Pinsky, Benjamin A Montez Rath, Maria E Wang, Hannah Miller, Jacob A Skhiri, Mehdi Shepard, John Mathew, Roshni Lee, Grace Bohman, Bryan Parsonnet, Julie Holubar, Marisa |
author_sort | Jacobson, Karen B |
collection | PubMed |
description | BACKGROUND: Although mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines report >90% efficacy, breakthrough infections occur. Little is known about their effectiveness against SARS-CoV-2 variants, including the highly prevalent B.1.427/B.1.429 variant. METHODS: In this quality improvement project, we collected demographic and clinical information from post-vaccine SARS-CoV-2 cases (PVSCs), defined as healthcare personnel (HCP) with positive SARS-CoV-2 nucleic acid amplification test after receiving ≥1 vaccine dose. Available specimens were tested for L452R, N501Y, and E484K mutations using reverse-transcription polymerase chain reaction. Mutation prevalence was compared among unvaccinated, early post-vaccinated (≤14 days after dose 1), partially vaccinated (positive test >14 days after dose 1 and <14 days after dose 2), and fully vaccinated (>14 days after dose 2) PVSCs. RESULTS: From December 2020 to April 2021, ≥23 090 HCP received ≥1 dose of an mRNA-based SARS-CoV-2 vaccine, and 660 HCP cases of SARS-CoV-2 occurred, of which 189 were PVSCs. Among the PVSCs, 114 (60.3%), 49 (25.9%), and 26 (13.8%) were early post-vaccination, partially vaccinated, and fully vaccinated, respectively. Of 261 available samples from vaccinated and unvaccinated HCP, 103 (39.5%), including 42 PVSCs (36.5%), had the L452R mutation presumptive of B.1.427/B.1.429. When adjusted for community prevalence of B.1.427/B.1.429, PVSCs did not have significantly elevated risk of B.1.427/B.1.429 compared with unvaccinated HCP. CONCLUSIONS: Most PVSCs occurred prior to expected onset of full, vaccine-derived immunity. Presumptive B.1.427/B.1.429 was not more prevalent in post-vaccine cases than in unvaccinated SARS-CoV-2 HCP. Continued infection control measures, particularly <14 days post-vaccination, and continued variant surveillance in PVSCs are imperative to control future SARS-CoV-2 surges. |
format | Online Article Text |
id | pubmed-8344553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-83445532021-08-10 Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center Jacobson, Karen B Pinsky, Benjamin A Montez Rath, Maria E Wang, Hannah Miller, Jacob A Skhiri, Mehdi Shepard, John Mathew, Roshni Lee, Grace Bohman, Bryan Parsonnet, Julie Holubar, Marisa Clin Infect Dis Major Articles and Commentaries BACKGROUND: Although mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines report >90% efficacy, breakthrough infections occur. Little is known about their effectiveness against SARS-CoV-2 variants, including the highly prevalent B.1.427/B.1.429 variant. METHODS: In this quality improvement project, we collected demographic and clinical information from post-vaccine SARS-CoV-2 cases (PVSCs), defined as healthcare personnel (HCP) with positive SARS-CoV-2 nucleic acid amplification test after receiving ≥1 vaccine dose. Available specimens were tested for L452R, N501Y, and E484K mutations using reverse-transcription polymerase chain reaction. Mutation prevalence was compared among unvaccinated, early post-vaccinated (≤14 days after dose 1), partially vaccinated (positive test >14 days after dose 1 and <14 days after dose 2), and fully vaccinated (>14 days after dose 2) PVSCs. RESULTS: From December 2020 to April 2021, ≥23 090 HCP received ≥1 dose of an mRNA-based SARS-CoV-2 vaccine, and 660 HCP cases of SARS-CoV-2 occurred, of which 189 were PVSCs. Among the PVSCs, 114 (60.3%), 49 (25.9%), and 26 (13.8%) were early post-vaccination, partially vaccinated, and fully vaccinated, respectively. Of 261 available samples from vaccinated and unvaccinated HCP, 103 (39.5%), including 42 PVSCs (36.5%), had the L452R mutation presumptive of B.1.427/B.1.429. When adjusted for community prevalence of B.1.427/B.1.429, PVSCs did not have significantly elevated risk of B.1.427/B.1.429 compared with unvaccinated HCP. CONCLUSIONS: Most PVSCs occurred prior to expected onset of full, vaccine-derived immunity. Presumptive B.1.427/B.1.429 was not more prevalent in post-vaccine cases than in unvaccinated SARS-CoV-2 HCP. Continued infection control measures, particularly <14 days post-vaccination, and continued variant surveillance in PVSCs are imperative to control future SARS-CoV-2 surges. Oxford University Press 2021-06-17 /pmc/articles/PMC8344553/ /pubmed/34137815 http://dx.doi.org/10.1093/cid/ciab554 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Articles and Commentaries Jacobson, Karen B Pinsky, Benjamin A Montez Rath, Maria E Wang, Hannah Miller, Jacob A Skhiri, Mehdi Shepard, John Mathew, Roshni Lee, Grace Bohman, Bryan Parsonnet, Julie Holubar, Marisa Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center |
title | Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center |
title_full | Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center |
title_fullStr | Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center |
title_full_unstemmed | Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center |
title_short | Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center |
title_sort | post-vaccination severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections and incidence of the presumptive b.1.427/b.1.429 variant among healthcare personnel at a northern california academic medical center |
topic | Major Articles and Commentaries |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344553/ https://www.ncbi.nlm.nih.gov/pubmed/34137815 http://dx.doi.org/10.1093/cid/ciab554 |
work_keys_str_mv | AT jacobsonkarenb postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT pinskybenjamina postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT montezrathmariae postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT wanghannah postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT millerjacoba postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT skhirimehdi postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT shepardjohn postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT mathewroshni postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT leegrace postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT bohmanbryan postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT parsonnetjulie postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter AT holubarmarisa postvaccinationsevereacuterespiratorysyndromecoronavirus2sarscov2infectionsandincidenceofthepresumptiveb1427b1429variantamonghealthcarepersonnelatanortherncaliforniaacademicmedicalcenter |